The world's scientific and social network for malaria professionals
Subscribe to free Newsletter | 10372 malaria professionals are enjoying the free benefits of MalariaWorld today

dihydroartemisinin-piperaquine

Mass drug administrations with dihydroartemisinin-piperaquine and single low dose primaquine to eliminate Plasmodium falciparum have only a transient impact on Plasmodium vivax: Findings from randomised controlled trials

February 14, 2020 - 16:53 -- Open Access
Author(s): 
Phommasone K, van Leth F, von Seidlein L, et al.
Reference: 
PLoS ONE 15(2): e0228190

Mass administrations of antimalarial drugs (MDA) have reduced the incidence and prevalence of P. falciparum infections in a trial in the Greater Mekong Subregion. Here we assess the impact of the MDA on P. vivax infections.

NOT Open Access | Artemether-lumefantrine and Dihydroartemisinin-Piperaquine Retain High Efficacy for Treatment of Uncomplicated Plasmodium falciparum Malaria in Myanmar

December 23, 2019 - 14:33 -- NOT Open Access
Author(s): 
Han KT, Lin K, Nyunt MM, et al.
Reference: 
Am J Trop Med Hyg. 2019 Dec 12

The emergence of artemisinin-resistant Plasmodium falciparum in the Greater Mekong Subregion threatens both the efficacy of artemisinin-based combination therapy (ACT), the first-line treatment for malaria, and prospects for malaria elimination. Monitoring of ACT efficacy is essential for ensuring timely updates to elimination policies and treatment recommendations. In 2014–2015, we assessed the therapeutic efficacies of artemether–lumefantrine (AL) and dihydroartemisinin–piperaquine (DP) for the treatment of uncomplicated P. falciparum at three study sites in Rakhine, Shan, and Kachin states in Myanmar.

Gametocyte clearance in children, from western Kenya, with uncomplicated Plasmodium falciparum malaria after artemether-lumefantrine or dihydroartemisinin-piperaquine treatment

December 10, 2019 - 08:22 -- Open Access
Author(s): 
Omondi P, Burugu M, Matoke-Muhia D, Too E, Nambati EA, Chege W, Musyoka KB, Thiongo K, Otinga M, Muregi F, Kimani F.
Reference: 
Malar J. 2019 Dec 4; 18(1):398

The efficacy and safety of artemether–lumefantrine (AL) and dihydroartemisinin–piperaquine (DP) against asexual parasites population has been documented. However, the effect of these anti-malarials on sexual parasites is still less clear. Gametocyte clearance following treatment is essential for malaria control and elimination efforts; therefore, the study sought to determine trends in gametocyte clearance after AL or DP treatment in children from a malaria-endemic site in Kenya.

NOT Open Access | Regulated rutin co-administration reverses mitochondrial-mediated apoptosis in Plasmodium berghei-infected mice

November 27, 2019 - 16:21 -- NOT Open Access
Author(s): 
Oludele OJ, Adisa BA, Olufunso OO.
Reference: 
Biochem Biophys Res Commun. 2019 Nov 22. pii: S0006-291X(19)32187-4.

Malarial infection causes apoptosis in hepatocytes. However, it is not known if co-administration of antimalarial drug with rutin will reverse the apoptotic effects of malarial infection. Plasmodium berghei-infected mice were assigned into groups as follows: groups I to III were treated with the vehicle (Parasitised Untreated, PU), 10 mg/kg body weight of Artesunate-Mefloquine (AM) and Dihydroartemisinin-Piperaquine (DP) respectively.

The efficacy of dihydroartemisinin-piperaquine and artemether-lumefantrine with and without primaquine on Plasmodium vivax recurrence: A systematic review and individual patient data meta-analysis

October 15, 2019 - 15:36 -- Open Access
Author(s): 
Robert J. Commons, Julie A. Simpson, Ric N. Price, et al.
Reference: 
PLoS Med 16(10): e1002928

Artemisinin-based combination therapy (ACT) is recommended for uncomplicated Plasmodium vivax malaria in areas of emerging chloroquine resistance. We undertook a systematic review and individual patient data meta-analysis to compare the efficacies of dihydroartemisinin-piperaquine (DP) and artemether-lumefantrine (AL) with or without primaquine (PQ) on the risk of recurrent P. vivax.

Medical Condition: 

Plasmodium falciparum dihydroartemisinin-piperaquine failures in Cambodia are associated with mutant K13 parasites presenting high survival rates in novel piperaquine in vitro assays: retrospective and prospective investigations

January 5, 2016 - 15:13 -- Open Access
Author(s): 
Duru V, Khim N, Menard D, et al.
Reference: 
BMC Medicine 2015, 13 :305 (22 December 2015)

The prospective study assessed ex vivo PSA survival rate alongside K13 polymorphism of isolates collected from patients enrolled in an open-label study with dihydroartemisinin-piperaquine for uncomplicated P. falciparum malaria in Cambodia (registered ACTRN12615000696594).

Country: 

Maximizing antimalarial efficacy and the importance of dosing strategies

May 12, 2015 - 15:57 -- Open Access
Author(s): 
James G Beeson, Philippe Boeuf and Freya JI Fowkes
Reference: 
BMC Medicine 2015, 13:110

In the most recent study, an analysis of clinical trials of artesunate-amodiaquine, widely used among children in Africa, revealed a superior efficacy for fixed-dose combination tablets compared to loose non-fixed dose combinations.

In vivo monitoring of dihydroartemisinin-piperaquine sensitivity in Plasmodium falciparum along the China-Myanmar border of Yunnan Province, China from 2007 to 2013

February 26, 2015 - 14:49 -- Open Access
Author(s): 
Hui Liu, Heng-lin Yang, Jian-wei Xu, et al.
Reference: 
Malaria Journal 2015, 14:47 (5 February 2015)

 Polymerase chain reaction (PCR) was conducted to distinguish between re-infection and recrudescence, to confirm the Plasmodium species. The data were entered and analysed by the Kaplan-Meier method. Treatment outcome was assessed according to the WHO recommended standards.

The diminishing returns of atovaquone-proguanil for elimination of Plasmodium falciparum malaria: modelling mass drug administration and treatment

September 30, 2014 - 19:40 -- Open Access
Author(s): 
Maude RJ, Nguon C, Dondorp AM, White LJ, White NJ
Reference: 
Malaria Journal 2014, 13 :380 (24 September 2014)

A deterministic, population level, mathematical model was developed based on data from Cambodia to explore the possible effects of large-scale use of A-P compared to dihydroartemisinin-piperaquine ACT for mass drug administration and/or treatment of P. falciparum malaria, with and without adjunctive primaquine (PQ) and long-lasting insecticide-treated bed nets (LLIN). The aim was local elimination.

Optimizing the programmatic deployment of the anti-malarials artemether-lumefantrine and dihydroartemisinin-piperaquine using pharmacological modelling

April 16, 2014 - 19:05 -- Open Access
Author(s): 
Hodel EM, Kay K, Hayes DJ, Terlouw DJ, Hastings IM
Reference: 
Malaria Journal 2014, 13 :138 (7 April 2014)

The model highlights the sub-optimally low ratio of DHA:PPQ which, in combination with the narrow therapeutic dose range of PPQ compared to DHA that drives the weight or age cut-offs, leaves DHA at a high risk of under-dosing.

Pages

Subscribe to RSS - dihydroartemisinin-piperaquine